Metastatic Breast Cancer Clinical Trials

A listing of 75 Metastatic Breast Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Metastatic Breast Cancer

1 - 12 of 75

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 75 active clinical trials seeking participants for Metastatic Breast Cancer research studies. The states with the highest number of trials for Metastatic Breast Cancer participants are Texas, California, Florida and New York.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

NCT06756932

Recruiting

The purpose of this study is to assess the safety and tolerability of BGB-21447 (a B-cell leukemia/lymphoma 2 inhibitor, Bcl-2i) in combination with fulvestrant, with or without BGB-43395 (cyclin-dependent kinase 4 inhibitor, CDK4i), in adults with HR+/HER2- metastatic breast cancer.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/21/2025

Locations: Hoag Memorial Presbyterian, Newport, California +14 locations

Conditions: Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer

Learn More ›

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

NCT06428396

Recruiting

The purpose of this study is to assess the efficacy and safety of belzutifan (MK-6482) plus fulvestrant compared to everolimus plus endocrine therapy (ET) (investigator's choice of fulvestrant or exemestane) in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) unresectable metastatic breast cancer. There is no formal hypothesis testing in this study.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/20/2025

Locations: USC/Norris Comprehensive Cancer Center ( Site 0013), Los Angeles, California +24 locations

USC/Norris Comprehensive Cancer Center ( Site 0013), Los Angeles, California

USC Norris Oncology Hematology Newport Beach ( Site 0029), Newport Beach, California

Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0011), Marietta, Georgia

CHRISTUS Highland ( Site 0005), Shreveport, Louisiana

Renown Regional Medical Center ( Site 0018), Reno, Nevada

Centro de Investigaciones Metabólicas (CINME)-Oncology ( Site 0504), Caba, Buenos Aires

Hospital Británico de Buenos Aires-Oncology ( Site 0500), Ciudad autónoma de Buenos Aires, Buenos Aires

Instituto de Investigaciones Clínicas Mar del Plata ( Site 0502), Mar del Plata, Buenos Aires

Instituto Alexander Fleming-Alexander Fleming ( Site 0505), Ciudad Autónoma de Buenos Aires, Caba

Sanatorio Allende - Cerro-Oncology ( Site 0506), Córdoba, Cordoba

Instituto de Oncología de Rosario ( Site 0501), Rosario, Santa Fe

Centro de Investigación del Maule ( Site 4106), Talca, Maule

Bradfordhill ( Site 4100), Santiago., Region M. De Santiago

FALP ( Site 4102), Santiago, Region M. De Santiago

Pontificia Universidad Catolica de Chile ( Site 4108), Santiago, Region M. De Santiago

Seoul National University Hospital ( Site 3100), Seoul, Not set

Samsung Medical Center ( Site 3101), Seoul, Not set

National Taiwan University Hospital ( Site 3301), Taipei, Not set

National Taiwan University Cancer Center ( Site 3302), Taipei, Not set

Faculty of Medicine - Khon Kaen University ( Site 3502), Muang, Khon Kaen

Faculty of Medicine Siriraj Hospital ( Site 3500), Bangkoknoi, Krung Thep Maha Nakhon

Songklanagarind Hospital ( Site 3501), Hat Yai, Songkhla

The Royal Cornwall Hospital ( Site 1904), Truro, England

St Bartholomews Hospital ( Site 1900), London, London, City Of

The Christie Hospital NHS Foundation Trust ( Site 1902), Withington, Manchester

Conditions: Metastatic Breast Cancer

Learn More ›

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

NCT06324357

Recruiting

This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment was not successful. The purpose of this study is to find a suitable dose of zongertinib that people with different types of HER2+ cancer that has spread can tolerate best when taken together with trastuzumab deruxtecan (T-DXd) or with trastuzumab emtansine (T-DM1... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/19/2025

Locations: Valkyrie Clinical Trials, Los Angeles, California +45 locations

Valkyrie Clinical Trials, Los Angeles, California

University of California Irvine, Orange, California

Sharp Memorial Hospital, San Diego, California

Yale University School of Medicine, New Haven, Connecticut

University of Iowa Hospitals & Clinics PARENT, Iowa City, Iowa

The Methodist Hospital Research Institute, Houston, Texas

Virginia Cancer Specialists, PC, Fairfax, Virginia

Fred Hutchinson Cancer Research Center, Seattle, Washington

UZ Leuven, Leuven, Not set

Centre Hospitalier de l'Ardenne, Libramont-Chevigny, Not set

Centre Hospitalier Universitaire de Liège, Liege, Not set

CHU UCL Namur - Site De Sainte-Elisabeth, Namur, Not set

The tumor hospital of Jilin Province, Changchun, Not set

The First Hospital of Jilin University, Changchun, Not set

Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, Not set

Harbin Medical University Cancer Hospital, Harbin, Not set

Jiangsu Province Hospital, Nanjing, Not set

Fudan University Shanghai Cancer Center, Shanghai, Not set

Tianjin Cancer Hospital, Tianjin, Not set

Henan Cancer Hospital, Zhengzhou, Not set

Istituto Di Candiolo, Candiolo (TO), Not set

Az.Osp. Universitaria "Ospedali Riuniti", Foggia, Not set

Istituto Scientifico Romagnolo, Meldola (fc), Not set

IRCCS San Raffaele, Milano, Not set

Istituto Europeo di Oncologia, Milano, Not set

Istituto Nazionale IRCCS Tumori Fondazione Pascale, Napoli, Not set

Istituto Clinico Humanitas, Rozzano, Not set

Aichi Cancer Center Hospital, Aichi, Nagoya, Not set

Hakuaikai Sagara Hospital, Kagoshima-shi, Not set

Tokai University Hospital, Kanagawa, Isehara, Not set

Kanagawa Cancer Center, Kanagawa, Yokohama, Not set

National Cancer Center Hospital East, Kashiwa-shi, Not set

Kyoto University Hospital, Kyoto, Kyoto, Not set

Osaka International Cancer Institute, Osaka-shi, Not set

Japanese Foundation for Cancer Research, Tokyo, Koto-ku, Not set

Hospital Teresa Herrera, A Coruña, Not set

Hospital del Mar, Barcelona, Not set

Hospital Vall d'Hebron, Barcelona, Not set

Servicio de Oncología Médica, Barcelona, Not set

Hospital General Universitario Gregorio Marañón, Madrid, Not set

Clínica Universidad de Navarra - Madrid, Madrid, Not set

Fundación Jiménez Díaz, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital La Paz, Madrid, Not set

CIO Clara Campal, Madrid, Not set

Hospital Universitario Virgen Macarena, Sevilla, Not set

Conditions: Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma

Learn More ›

A Study of Alisertib in Combination with Endocrine Therapy in Patients with HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

NCT06369285

Recruiting

PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two prior lines of endocrine therapy in the recurrent or metastatic setting. This study is intended to evaluate the optimal alisertib dose administered in combination with the selected endocrine therapy. The study is a... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/19/2025

Locations: Alabama Oncology, Birmingham, Alabama +25 locations

Alabama Oncology, Birmingham, Alabama

Mayo Clinic Hospital, Phoenix, Arizona

City of Hope at Orange County Lennar Foundation Cancer Center, Irvine, California

LA Cancer Network, Los Angeles, California

UCLA Department of Medicine - Hematology/Oncology, Los Angeles, California

University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San Francisco, California

University of Colorado School of Medicine, Aurora, Colorado

Yale University, Yale Cancer Center, New Haven, Connecticut

Mayo Clinic Florida, Jacksonville, Florida

Cancer Specialists of North Florida, Jacksonville, Florida

Winship Cancer Institute, Emory University, Atlanta, Georgia

The University of Chicago, Chicago, Illinois

Mayo Clinic, Rochester, Minnesota

Washington University School of Medicine, Saint Louis, Missouri

Oncology Hematology Associates, Springfield, Missouri

UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

The Ohio State University, Stefanie Spielman Comprehensive Breast Center, Columbus, Ohio

Taylor Cancer Research Center, Maumee, Ohio

Alliance Cancer Specialists, Horsham, Pennsylvania

Texas Oncology, Dallas, Texas

Virginia Cancer Institute, Richmond, Virginia

Hospital General Universitario Dr. Balmis, Alicante, Not set

Hospital Clínico de Barcelona, Barcelona, Not set

Hospital San Pedro de Alcántara, Cáceres, Not set

Hospital Universitario Arnau de Vilanova, Lleida, Not set

Hospital Clínico Universitario de Valencia, València, Not set

Conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer

Learn More ›

SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

NCT05846789

Recruiting

This is a randomized Phase II study of standard of care (SOC) chemotherapy monotherapy vs. SOC chemotherapy combined with tocilizumab in in Black and non-Black patients with metastatic triple negative or ER low breast cancer.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/14/2025

Locations: IU Health Joe and Shelly Schwarz Cancer Center, Carmel, Indiana +3 locations

Conditions: Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-low Breast Cancer

Learn More ›

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

NCT05894239

Recruiting

This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after induction therapy in participants with previously untreated HER2-positive advanced breast cancer (ABC).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/13/2025

Locations: Banner Health MD Anderson AZ, Gilbert, Arizona +160 locations

Banner Health MD Anderson AZ, Gilbert, Arizona

Disney Family Cancer Center, Burbank, California

Ellison Institute of Technology, Los Angeles, California

Georgetown Uni Hospital, Washington, District of Columbia

Medstar Research Institute, Hyattsville, Maryland

Dana Farber Cancer Institute, Boston, Massachusetts

Henry Ford Hospital, Detroit, Michigan

Renown Regional Medical Center, Reno, Nevada

Hackensack University Medical Center, Hackensack, New Jersey

Atrium Health, Charlotte, North Carolina

Hightower Clinical, Oklahoma City, Oklahoma

Renovatio Clinical - El Paso, El Paso, Texas

JPS Health Network, Fort Worth, Texas

Lumi Research, Kingwood, Texas

Renovatio Clinical, The Woodlands, Texas

Kadlec Clinic Hematology and Oncology, Kennewick, Washington

Swedish Medical Center, Seattle, Washington

Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Not set

Centro Oncologico Korben, Ciudad Autonoma Buenos Aires, Not set

Instituto de Oncología de Rosario, Rosario, Not set

Hospital Provincial del Centenario, Rosario, Not set

CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica, San Juan, Not set

Clínica Viedma, Viedma Rio Negro, Not set

Blacktown Hospital, Blacktown, New South Wales

Kinghorn Cancer Centre, Darlinghurst, New South Wales

Gosford Hospital, Gosford, New South Wales

University of the Sunshine Coast, Sippy Downs, Queensland

Monash Health, Clayton, Victoria

Sir Charles Gairdner Hospital, Perth, Western Australia

Cliniques Universitaires St-Luc, Bruxelles, Not set

GHdC Site Les Viviers, Charleroi, Not set

Jessa Zkh (Campus Virga Jesse), Hasselt, Not set

Clinique Ste-Elisabeth, Namur, Not set

Hospital Sao Rafael - HSR, Salvador, Bahia

Crio - Centro Regional Integrado de Oncologia, Fortaleza, Ceará

Hospital Araujo Jorge, Goiania, Goiás

Hospital do Câncer de Londrina, Londrina, Paraná

Hospital do Cancer de Pernambuco - HCP, Recife, Pernambuco

Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul

Hospital Sao Lucas - PUCRS, Porto Alegre, Rio Grande Do Sul

Hospital de Amor Amazônia, Porto Velho, Rondônia

Hospital de Cancer de Barretos, Barretos, São Paulo

Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, São Paulo

Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda, Sao Paulo, São Paulo

Arthur J.E. Child Comprehensive Cancer Center-Calgary, Calgary, Alberta

The Moncton Hospital, Moncton, New Brunswick

Eastern Health - General Hospital, St. John's, Newfoundland and Labrador

Sunnybrook Health Sciences Centre, Toronto, Ontario

Centre Hospitalier de l?Université de Montréal (CHUM), Montreal, Quebec

Jewish General Hospital, Montreal, Quebec

Hôpital du Sacré-Coeur de Montreal, Montreal, Quebec

Hopital du Saint Sacrement, Quebec City, Quebec

Allan Blair Cancer Center, Regina, Saskatchewan

Affiliated Hospital of Hebei University, Baoding, Not set

Beijing Cancer Hospital, Beijing, Not set

The First Hospital of Jilin University, Changchun City, Not set

Sichuan Provincial Cancer Hospital, Chengdu, Not set

Sichuan Provincial People's Hospital, Chengdu, Not set

Fujian Cancer Hospital, Fuzhou, Not set

Zhejiang Cancer Hospital, Hangzhou City, Not set

Harbin Medical University Tumor Hospital, Harbin, Not set

Shandong Cancer Hospital, Jinan, Not set

The First Affiliated Hospital to Henan University of Science and Technology, Luoyang, Not set

The Second Affiliated Hospital to Nanchang University, Nanchang, Not set

Guangxi Cancer Hospital of Guangxi Medical University, Nanning, Not set

Shantou Center Hospital, Shantou City, Not set

Tianjin Cancer Hospital, Tianjin, Not set

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, Not set

Hubei Cancer Hospital, Wuhan, Not set

Clinica De La Costa, Barranquilla, Not set

Fundación CTIC - Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo, Bogota, D.C., Not set

Oncomedica S.A., Monteria, Not set

Sociedad de Oncología y hematología del Cesar Ltda, Valledupar, Not set

Tampere University Hospital, Tampere, Not set

Turku Uni Central Hospital, Turku, Not set

Institut Sainte Catherine, Avignon, Not set

Centre Hospitalier de La Cote Basque, Bayonne, Not set

Polyclinique Bordeaux Nord Aquitaine, Bordeaux, Not set

Klinikum St. Marien, Amberg, Not set

Marienhospital Bottrop gGmbH, Bottrop, Not set

Gynonco Düsseldorf, MVZ Medical Center GmbH, Düsseldorf, Not set

Frauenarztpraxis Dr. Apel, Dr. Kolpin, Erfurt, Not set

Praxis für Interdisziplinäre Onkologie und Hämatologie GbR, Freiburg, Not set

Klinik & Poliklinik für Frauenheilkunde und Geburtshilfe, Campus Innenstadt, München, Not set

Caritas Klinik St. Theresia -Frauenklinik Brustzentrum, Saarbruecken, Not set

Gynäkologie Kompetenzzentrum, Stralsund, Not set

Queen Mary Hospital, Hong Kong, Not set

Tuen Mun Hospital, Hong Kong, Not set

Max Super Speciality Hospital, NEW Delhi Delhi, Delhi

Sunshine Global Hospital (A unit of Baroda Medicare Pvt Ltd), Surat CITY, Gujarat

Artemis Hospital, Gurugram, Haryana

Tata Medical Center, Kolkata, WEST Bengal

I.R.S.T Srl IRCCS, Meldola, Emilia-Romagna

Ospedale San Giovanni Addolorata, Roma, Lazio

Ospedale San Raffaele, Milano, Lombardia

Irccs Istituto Nazionale Dei Tumori (Int), Milano, Lombardia

Irccs Istituto Europeo Di Oncologia (IEO), Milano, Lombardia

Ospedale San Gerardo, Monza, Lombardia

A.O.U. Maggiore della Carità, Novara, Piemonte

Casa di Cura La Maddalena, Palermo, Sicilia

Ospedale Santa Maria Annunziata, Bagno a Ripoli, Toscana

"Azienda Ospedaliera Universitaria Integrata Verona Ospedale Borgo Trento", Verona, Veneto

King Hussein Cancer Center, Amman, Not set

University of Nairobi - Institute of Tropical and Infectious Diseases, Nairobi, Not set

National Cancer Center, Goyang-si, Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital, Yonsei University Health System, Seoul, Not set

Asan Medical Center, Seoul, Not set

Gangnam Severance Hospital, Seoul, Not set

Samsung Medical Center, Seoul, Not set

Seoul St Mary's Hospital, Seoul, Not set

Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco

OncoMed, Ciudad de México, Mexico CITY (federal District)

Centro Oncológico Hematológico Roma, Mexico City, Mexico CITY (federal District)

Hospital Universitario, Monterrey, Nuevo LEON

CENEIT Oncologicos, Mexico City, Not set

Sultan Qaboos Comprehensive Cancer Care & Research Center, Muscat, Not set

Centrum Onkologii im. Prof. Franciszka ?ukaszczyka, Bydgoszcz, Not set

Uniwersyteckie Centrum Kliniczne, Gda?sk, Not set

Szpital Morski im.PCK, Gdynia, Not set

Narodowy Instytut Onkologii Odzia? w Gliwicach, Gliwice, Not set

Przychodnia Lekarska KOMED, Roman Karaszewski, Konin, Not set

Szpital Wojewódzki im. Miko?aja Kopernika, Koszalin, Not set

Wielkopolskie Centrum Onkologii im. Marii Sk?odowskiej-Curie, Pozna?, Not set

Centrum Onkologii Instytut im.M. Sklodowskiej-Curie, Warszawa, Not set

National University Hospital, Singapore, Not set

National Cancer Centre, Singapore, Not set

Icon Cancer Centre Farrer Park, Singapore, Not set

Tan Tock Seng Hospital, Singapore, Not set

Hopelands Cancer Centre, Hilton, Not set

Charlotte Maxeke Academic Hospital, Johannesburg, Not set

Medical Oncology Centre of Rosebank, Johannesburg, Not set

Limpopo Cancer Research Institute, Polokwane, Not set

Steve Biko Academic Hospital, Pretoria, Not set

Chris Hani Baragwanath Clinical Trial Site, Soweto, Not set

Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruña, LA Coruna

Hospital Universitari Dexeus - Grupo Quironsalud, Barcelona, Not set

Hospital Universitari Vall d'Hebron, Barcelona, Not set

Hospital General Universitario Gregorio Marañon, Madrid, Not set

Hospital Ramon y Cajal, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Clinico Universitario Virgen de la Victoria, Malaga, Not set

Hospital Universitario Virgen Macarena, Sevilla, Not set

National Taiwan Uni Hospital, Taipei, Not set

Tri-Service General Hospital, Taipei, Not set

Chang Gung Memorial Hospital-Linkou, Taoyuan County, Not set

Abderrahmen Mami Hospital, Ariana, Not set

Farhat Hached Hospital, Sousse, Not set

Institut Salah Azeiz, Tunis, Not set

Gazi University Medical Faculty, Ankara, Not set

Bakirkoy Dr. Sadi Konuk Egitim ve Arastirma Hastanesi, Tibbi Onkoloji, Bakirkoy / Istanbul, Not set

Dicle University Faculty of Medicine, Diyarbakir, Not set

Medipol Mega Üniversite Hastanesi Göztepe, Istanbul, Not set

Katip Celebi University Ataturk Training and Research Hospital, Izmir, Not set

Medical Park Seyhan Hospital, Seyhan, Not set

Hacettepe Uni Medical Faculty Hospital, Sihhiye/Ankara, Not set

Blackpool Victoria Hospital, Blackpool, Not set

Colchester General Hospital, Colchester, Essex, Not set

Mount Vernon Hospital, Northwood, Not set

Nottingham City Hospital, Nottingham, Not set

Churchill Hospital, Oxford, Not set

Conditions: Metastatic Breast Cancer

Learn More ›

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

NCT06072612

Recruiting

This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/12/2025

Locations: Comprehensive Blood and Cancer Center, Bakersfield, California +47 locations

Comprehensive Blood and Cancer Center, Bakersfield, California

Hoag Hospital Center, Irvine, California

Hoag Hospital Irvine, Irvine, California

UC San Diego, San Diego, California

St. John's Cancer Center, Santa Monica, California

Torrance Memorial Cancer Center, Torrance, California

Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut

University of Miami-SCCC-Lennar, Coral Gables, Florida

University Of Miami-SCCC-Miami, Miami, Florida

Advent Health - Orlando, Orlando, Florida

University of Miami-SCCC-Plantation, Plantation, Florida

Northwestern University, Chicago, Illinois

Southern Illinois University-Simmons, Springfield, Illinois

Carle Foundation Cancer Institute-Urbana, Urbana, Illinois

Northwest Cancer Center, Dyer, Indiana

AMR Kansas City Oncology, Kansas City, Kansas

Care Access-Marrero, Marrero, Louisiana

The Center for Cancer and Blood Disorders a division of American Oncology Partners, P.A., Bethesda, Maryland

Nebraska Cancer Specialists, Omaha, Nebraska

New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C. (Babylon), Babylon, New York

New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C (Brox), Bronx, New York

New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C.(New Hyde Park), New Hyde Park, New York

Manhattan Hematology /Oncology Associates, New York, New York

New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C (NY), New York, New York

New York Cancers & Blood Specialists_North Shore Hematology Oncology Assocaites P.C (Patchogue), Patchogue, New York

New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C. (Port Jefferson Station2), Port Jefferson Station, New York

New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C.(Port Jefferson Station1), Port Jefferson Station, New York

New York Cancers & Blood Specialists, Port Jefferson Station, New York

New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C. (Riverhead), Riverhead, New York

Gabrail Cancer & Research Center, Canton, Ohio

Cleveland Clinic, Cleveland, Ohio

Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas

Mary Crowley Cancer Research, Dallas, Texas

DHR Health Oncology Institute, Edinburg, Texas

Texas Oncology - Fredericksburg, Fredericksburg, Texas

Texas Oncology - Harlingen, Harlingen, Texas

Texas Oncology McAllen, McAllen, Texas

Texas Oncology, New Braunfels, New Braunfels, Texas

Texas Oncology-San Antonio Cancer Care, San Antonio, Texas

Texas Oncology - San Antonio Northeast, San Antonio, Texas

Texas Oncology - San Antonio Stone Oak, San Antonio, Texas

Tranquil Clinical Research, Webster, Texas

Texas Oncology - Weslaco, Weslaco, Texas

Hematology-Oncology Associates of Fredericksburg, Inc, Fredericksburg, Virginia

Cancer Care Northwest, Spokane Valley, Washington

Cancer Care Northwest-1 (601 S. Sherman), Spokane, Washington

Cancer Care Northwest_2 (605 E. Holland), Spokane, Washington

Sheboygan Cancer & Blood Specialists, Sheboygan, Wisconsin

Conditions: Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer

Learn More ›

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

NCT03424005

Recruiting

This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages. During Stage 1, four cohorts will be enrolled in parallel in this study: Cohort 1 will consist of Programmed death-ligand 1 (PD-L1)-positive participants who have received no prior systemic therapy for metastatic or inoperable locally advanced triple-negative breast cancer (TNBC)... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/07/2025

Locations: City of Hope, Duarte, California +38 locations

City of Hope, Duarte, California

University of California San Diego Medical Center, La Jolla, California

Stanford Cancer Institute, Stanford, California

Rocky Mountain Cancer Center - Longmont, Longmont, Colorado

H. Lee Moffitt Cancer Center and Research Inst., Tampa, Florida

Hackensack Univ Medical Center, Hackensack, New Jersey

Regional Cancer Care Associates, LLC, Howell, New Jersey

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

NYU Langone Medical Center, New York, New York

Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

The West Clinic, Germantown, Tennessee

Vanderbilt University Medical Center, Nashville, Tennessee

Texas Oncology-Plano East, Plano, Texas

Peter MacCallum Cancer Centre-East Melbourne, Melbourne, Victoria

Fiona Stanley Hospital - Medical Oncology, Murdoch, Western Australia

Centre Léon Bérard, Lyon, Not set

Institut régional du Cancer Montpellier, Montpellier, Not set

Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, Not set

Gustave Roussy, Villejuif CEDEX, Not set

Universitätsklinikum Erlangen, Erlangen, Not set

Universitätsklinikum Essen, Essen, Not set

Shaare Zedek Medical Center, Jerusalem, Not set

Hadassah University Medical Center, Jerusalem, Not set

Rabin MC, Petach Tikva, Not set

Sheba Medical Center, Ramat Gan, Not set

Tel-Aviv Sourasky Medical Center, Tel Aviv, Not set

National Cancer Center Clinical Trials Center / Center for Breast Cancer, Goyang-si, Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital, Seoul, Not set

University of Ulsan College of Medicine - Asan Medical Center, Seoul, Not set

Samsung Medical Center, Seoul, Not set

Hospital del Mar, Barcelona, Not set

Vall d?Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, Not set

Hospital Universitario Ramon y Cajal, Madrid, Not set

Centro Integral Oncológico Clara Campal Ensayos Clínicos START, Madrid, Not set

Hospital Universitario Virgen Macarena, Sevilla, Not set

Beatson West of Scotland Cancer Centre, Glasgow, Not set

Barts Health NHS Trust - St Bartholomew's Hospital, London, Not set

Conditions: Metastatic Breast Cancer

Learn More ›

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

NCT06120283

Recruiting

This is a dose escalation and dose expansion study to compare how well BGB-43395, a cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with either fulvestrant or letrozole in participants with hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer (BC) and other advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-43395.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/07/2025

Locations: Sarah Cannon Research Institute (Scri) At Health One, Denver, Colorado +64 locations

Sarah Cannon Research Institute (Scri) At Health One, Denver, Colorado

Florida Cancer Specialists and Research Institute, Lake Mary, Florida

Karmanos Cancer Institute, Detroit, Michigan

Washington University School of Medicine, Saint Louis, Missouri

Duke Cancer Center, Durham, North Carolina

James Cancer Hospital and Solove Research Institute, Columbus, Ohio

Scri Oncology Partners, Nashville, Tennessee

The University of Texas Md Anderson Cancer Center, Houston, Texas

Next Dallas, Irving, Texas

Next Oncology, San Antonio, Texas

Blacktown Cancer and Haematology Centre, Blacktown, New South Wales

Southern Highlands Private Hospital, Bowral, New South Wales

Concord Repatriation General Hospital, Concord, New South Wales

Macquarie University, North Ryde, New South Wales

Townsville University Hospital, Douglas, Queensland

Genesiscare St Andrews, Adelaide, South Australia

Austin Health, Heidelberg, Victoria

Peter Maccallum Cancer Centre, Melbourne, Victoria

Fundacao Pio Xii Hospital de Amor de Barretos, Barretos, Not set

Hospital Sirio Libanes Brasilia, Brasilia, Not set

Centro de Pesquisas Oncologicas Cepon, Florianopolis, Not set

Liga Norte Riograndene Contra O Cancer, Natal, Not set

Fundacao Universidade de Caxias Do Sul Instituto de Pesquisas Em Saude, Petropolis, Not set

Hospital Sao Lucas Da Pucrs Uniao Brasileira de Educacao E Assistencia, Porto Algre, Not set

Instituto Nacional de Cancer, Rio de Janeiro, Not set

Instituto Dor de Pesquisa E Ensino Hospital Sao Rafael, Salvador, Not set

Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira, Sao Paulo, Not set

Clinica de Pesquisa E Centro de Estudos Em Oncologia Ginecologica E Mamaria, Sao Paulo, Not set

Hospital Israelita Albert Einstein, Sao Paulo, Not set

Beijing Cancer Hospital, Beijing, Beijing

Fujian Cancer Hospital, Fuzhou, Fujian

Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South), Guangzhou, Guangdong

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang

The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang, Jiangxi

Liaoning Cancer Hospital and Institute, Shenyang, Liaoning

Fudan University Shanghai Cancer Centerpudong, Shanghai, Shanghai

Centre de Lutte Contre Le Cancer Institut Bergonie, Bordeaux, Not set

Centre Francois Baclesse, Caen Cedex, Not set

Centre Oscar Lambret, Lille, Not set

Institut Paoli Calmettes, Marseille, Not set

Institut Curie, Paris, Not set

Centre Eugene Marquis, Rennes, Not set

Institut de Cancerologie de Louest, St Herblain, Not set

Institut Gustave Roussy, Villejuif, Not set

Nagoya University Hospital, Nagoya, Aichi

National Cancer Center Hospital East, Kashiwa, Chiba

Shizuoka Cancer Center, Suntogun, Shizuoka

Seoul National University Bundang Hospital, Seongnamsi, Gyeonggi-do

Korea University Anam Hospital, Seoul, Gyeonggi-do

Gachon University Gil Medical Center, Incheon, Incheon Gwang'yeogsi

Seoul National University Hospital, Seoul, Seoul Teugbyeolsi

Severance Hospital Yonsei University Health System, Seoul, Seoul Teugbyeolsi

Asan Medical Center, Seoul, Seoul Teugbyeolsi

Samsung Medical Center, Seoul, Seoul Teugbyeolsi

The Catholic University of Korea, Seoul St Marys Hospital, Seoul, Seoul Teugbyeolsi

Pulau Pinang Hospital, Georgetown, Not set

University Malaya Medical Centre, Kuala Lumpur, Not set

Sarawak General Hospital, Kuching, Not set

National Cancer Institute (Institut Kanser Negara), Putrajaya, Not set

The Institute of Oncology, Arensia Exploratory Medicine, Chisinau, Not set

Harbour Cancer and Wellness, Auckland, Not set

Nzcr Christchurch, Christchurch, Not set

Siriraj Hospital, Bangkok, Not set

Banphaeo General Hospital, Banphaeo, Not set

Srinagarind Hospital (Khon Kaen University), Muang, Not set

Conditions: Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Non-small Cell Lung Cancer

Learn More ›

Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness

NCT05968144

Recruiting

Frailty is one of the main reasons older adults lose independence. Frailty describes a reduced ability to withstand stress on the physiological scale, or a reduced physiological reserve. The theory is that entrainment of circadian rhythm via time-restricted eating will improve the body's ability to predict energy supply and demand, and therefore enable the body to allocate more resources to anabolic processes and promote resilience to cancer treatment, thereby preventing the progression of frail... Read More

Gender:

ALL

Ages:

55 years and above

Trial Updated:

03/07/2025

Locations: University of Maryland, Baltimore, Baltimore, Maryland

Conditions: Prostatic Neoplasm, Survivorship, Frailty, Aging, Metastatic Breast Cancer

Learn More ›

Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

NCT04115306

Recruiting

The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer. PMD-026 is a targeted oral agent designed to kill tumor cells in metastatic breast cancer.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/06/2025

Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +7 locations

Conditions: Metastatic Breast Cancer

Learn More ›

Primary Breast Oligoprogressive Sites Treated with Radiotherapy to Obviate the Need to Change Systemic Therapy

NCT06055881

Recruiting

This study assesses if metastasis-directed radiation therapy (Stereotactic body radiation therapy - SBRT) can delay a change in systemic therapy, and if circulating tumor cells in the bloodstream can help guide treatment options in metastatic breast cancer patients with progressive disease

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

03/03/2025

Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +1 locations

Conditions: Breast Carcinoma, Anatomic Stage IV Breast Cancer AJCC V8, Metastatic Breast Cancer

Learn More ›

1 - 12 of 75